Pediatric Rheumatology · Blau Syndrome

Treatment Options and Medication Safety

At a Glance

Blau syndrome treatment is individualized according to a child’s joint, skin, and eye inflammation. Steroids may control flares quickly, while methotrexate or biologics can reduce steroid use; regular eye exams and laboratory monitoring are essential because blood tests may miss active uveitis.

Managing Blau syndrome requires a specialized, collaborative approach. Because the condition is so rare, there is no single “one-size-fits-all” treatment plan or universally validated sequence that applies to every child ^[1]^[2]. Instead, pediatric rheumatologists and ophthalmologists consider commonly used options that scale up based on how your child’s body and eyes respond, prioritizing treatment based on organ involvement and severity ^[1].

The goal of treatment is to reach quiescence, a state where the inflammation is quiet and no longer causing damage to the eyes, joints, or skin ^[3]^[4]. Do not start, stop, taper, or change immunosuppressive medicines or steroid eye drops without the treating team.

Common Treatment Options

A child with threatening eye inflammation may need prompt systemic immunomodulation or a biologic without waiting for earlier steps to fail.

Bridging with Corticosteroids: When a child is first diagnosed or experiencing a significant flare-up, doctors often start with high-dose systemic corticosteroids (such as prednisone). These are powerful anti-inflammatory drugs that work quickly to “put out the fire” of active inflammation ^[1]^[5]. They are intended to be used for a short time. Because long-term steroid use can affect a child’s growth, blood pressure, glucose, and bone health, the care team will aim to taper (slowly reduce) the dose as soon as it is safe to do so ^[5]^[4].
Methotrexate: If the condition involves the joints or the eyes, doctors may use methotrexate ^[1]^[5]. This is a steroid-sparing agent, meaning it helps control the disease so the child can take less prednisone ^[6]^[5]. Methotrexate is typically given once a week, either as a pill or a small injection under the skin ^[6]^[5]. It requires regular CBC, liver, and renal monitoring, and a locally prescribed folic-acid schedule ^[6].
Biologic Therapy (TNF Inhibitors): If inflammation persists, or for severe uveitis, the care team may use a biologic medication. The most common biologics used for Blau syndrome are TNF inhibitors (TNFi), such as adalimumab or infliximab ^[1]^[7]. These drugs target a specific protein in the immune system ^[8]. Adalimumab is often given as an injection at home, and infliximab as an infusion (through an IV) in a clinic ^[3]^[8]. Schedules vary by age, indication, and response. If one TNF inhibitor does not work well enough or if the child’s eyes begin to flare again, the doctor may switch to a different drug ^[9]^[10].
Options for Refractory Disease: For cases that are refractory—meaning they don’t respond to standard treatments—specialists may look toward other targeted therapies. These are highly individualized options supported mainly by limited case-level evidence and are often off-label ^[1]. IL-1 Inhibitors (canakinumab, anakinra) and IL-6 Inhibitors (tocilizumab) have been used in some cases ^[11]^[2]^[4]^[12]. JAK Inhibitors (tofacitinib) are newer oral medications ^[13]^[14]. Age approvals, label-specific risks, and laboratory monitoring differ for these drugs.

Essential Safety and Monitoring

Because these treatments modify the immune system, your child will need regular check-ups to stay safe.

Infection Risk and Vaccines: Immunosuppressive therapies increase the risk of serious infections. Discuss an infection/fever and vaccination action plan with your doctor. Before starting biologics, your child will be assessed for tuberculosis and hepatitis ^[15]^[16]. Live-vaccine precautions apply while on biologics.
Lymphopenia and Labs: Medications like tofacitinib can lower white blood cells (lymphocytes) ^[17]. Regular blood tests are necessary to ensure these levels don’t drop too low ^[17].
Neurologic Symptoms: Although very rare, TNF inhibitors have been linked to unpredictable nerve issues, such as Guillain–Barré syndrome ^[18]. If facial drooping, slurred speech, or sudden weakness occurs, that is an emergency rather than merely something to report at the next opportunity ^[18].

The Critical Role of the Eye Exam

It is important to remember that blood tests (like ESR or CRP) do not always reflect what is happening inside the eyes ^[3]. A child’s systemic markers can look normal even while uveitis is actively flaring ^[3].

Because of this, regular ophthalmic exams are the only way to truly monitor eye health ^[19]^[20]. These comprehensive screenings must continue even if your child seems to be doing well, as “quiet” inflammation can still lead to complications like cataracts or glaucoma if left untreated ^[21]^[19]. Every dose and treatment decision will be individualized to your child’s weight, age, and specific symptoms ^[6]^[13].

Common questions in this guide

What is the goal of treatment for Blau syndrome?

The goal is quiescence, meaning inflammation is quiet and no longer damaging the eyes, joints, or skin. Pediatric rheumatology and ophthalmology teams adjust medicines based on organ involvement, severity, and the child’s response.

Why might my child receive methotrexate for Blau syndrome?

Methotrexate can help control joint or eye inflammation and reduce reliance on prednisone. It is usually taken once a week as a pill or an injection under the skin, with regular blood tests and a prescribed folic-acid plan.

When are adalimumab or infliximab used for Blau syndrome?

TNF inhibitors may be considered when inflammation persists or uveitis is severe. Adalimumab is usually given as an injection at home, while infliximab is given by IV infusion in a clinic; the choice depends on age, indication, response, and care needs.

What monitoring does a child on Blau syndrome treatment need?

Children may need regular blood counts and liver and kidney tests for some medicines, along with tuberculosis and hepatitis screening before biologic therapy. Regular eye exams are essential because ESR and CRP can be normal even when uveitis is active.

What symptoms need urgent medical attention during treatment?

Facial drooping, slurred speech, or sudden weakness while taking a TNF inhibitor can signal a rare neurologic problem and requires emergency evaluation. Fever or suspected infection should be handled according to the action plan from the treating team.

Can I stop or change my child’s Blau syndrome medicines at home?

No. Do not start, stop, taper, or change immunosuppressive medicines or steroid eye drops without instructions from the treating team, because inflammation can flare and corticosteroids may need to be reduced gradually.

Get notified when new evidence is published on Infantile onset panniculitis with uveitis and systemic granulomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (21)

1
Management of Blau syndrome: review and proposal of a treatment algorithm.
Lassoued Ferjani H, Kharrat L, Ben Nessib D, et al.
European journal of pediatrics 2024; (183(1)):1-7 doi:10.1007/s00431-023-05204-9.
PMID: 37735224
2
Treatment of uveitis in Blau syndrome: A systematic review and meta-analysis.
Maccora I, Wouters C, Rosè CD, et al.
Journal of autoimmunity 2025; (153()):103401 doi:10.1016/j.jaut.2025.103401.
PMID: 40147219
3
A Pediatric Case of Blau Syndrome with NOD2 p.Arg587Cys Mutation Successfully Managed with Infliximab: A Long-Term Follow-Up Study.
Sakono T, Mizuki Y, Takebayashi K, et al.
Ocular immunology and inflammation 2026; (34(6)):1371-1376 doi:10.1080/09273948.2026.2689371.
PMID: 42289393
4
Blau syndrome with good Reponses to Tocilizumab: A case report and focused literature review.
Lu L, Shen M, Jiang D, et al.
Seminars in arthritis and rheumatism 2018; (47(5)):727-731 doi:10.1016/j.semarthrit.2017.09.010.
PMID: 29110911
5
Childhood sarcoidosis: Louisiana experience.
Gedalia A, Khan TA, Shetty AK, et al.
Clinical rheumatology 2016; (35(7)):1879-84 doi:10.1007/s10067-015-2870-9.
PMID: 25616361
6
Case Report: Methotrexate and hydroxychloroquine in combination for the treatment of NOD2-mutation-associated Blau syndrome.
Jensen ME, Harrell K, McBride JD
Frontiers in immunology 2023; (14()):1279329 doi:10.3389/fimmu.2023.1279329.
PMID: 37868966
7
Blau syndrome: Lessons learned in a tertiary care centre at Chandigarh, North India.
Kumrah R, Pilania RK, Menia NK, et al.
Frontiers in immunology 2022; (13()):932919 doi:10.3389/fimmu.2022.932919.
PMID: 36189202
8
Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome.
Chen J, Luo Y, Zhao M, et al.
Arthritis research & therapy 2019; (21(1)):236 doi:10.1186/s13075-019-2017-5.
PMID: 31718710
9
Uveitis in sporadic Blau syndrome: Long-term follow-up of a refractory case treated successfully with adalimumab.
Naik AU, Annamalai R, Biswas J
Indian journal of ophthalmology 2018; (66(10)):1483-1485 doi:10.4103/ijo.IJO_629_18.
PMID: 30249847
10
Characterization of Blau syndrome panuveitis with wide-field fluorescein angiography.
DeSouza PJ, Shah R
American journal of ophthalmology case reports 2019; (14()):92-94 doi:10.1016/j.ajoc.2019.03.006.
PMID: 30989150
11
Persistent Tenosynovitis, Steroid Dependency and a Hyperpigmented Scaly Macular Rash in a Child With Juvenile Idiopathic Arthritis.
Papatesta EM, Kossiva L, Tsolia M, Maritsi D
Cureus 2020; (12(10)):e11208 doi:10.7759/cureus.11208.
PMID: 33269139
12
Granulomatous Tubulointerstitial Nephritis in a Kidney Allograft: Treatment with Interleukin-6 Receptor Antagonist Stabilises Kidney Function.
Doctor GT, Dudreuilh C, Perera R, Dorling A
Journal of clinical medicine 2024; (13(12)) doi:10.3390/jcm13123427.
PMID: 38929956
13
Tofacitinib effectiveness in Blau syndrome: a case series of Chinese paediatric patients.
Zhang S, Cai Z, Mo X, Zeng H
Pediatric rheumatology online journal 2021; (19(1)):160 doi:10.1186/s12969-021-00634-x.
PMID: 34781959
14
Effective Treatment of Janus Kinase 1/3 Inhibitor in Blau Syndrome From a Multicenter Retrospective Study in Central China.
Hu Y, Li P, Liu J, et al.
The Journal of rheumatology 2025; (52(8)):810-816 doi:10.3899/jrheum.2024-0822.
PMID: 40233998
15
Pediatric Sarcoidosis: A Review with Emphasis on Early Onset and High-Risk Sarcoidosis and Diagnostic Challenges.
Chiu B, Chan J, Das S, et al.
Diagnostics (Basel, Switzerland) 2019; (9(4)) doi:10.3390/diagnostics9040160.
PMID: 31731423
16
Familial Granulomatous Uveitis with Arthritis Suggestive of Blau Syndrome: A Multigenerational Case Series from India.
Jain P, Agrrawal V, Singla S, et al.
Ocular immunology and inflammation 2026; (34(4)):875-878 doi:10.1080/09273948.2026.2651789.
PMID: 41902739
17
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review.
Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, et al.
Therapeutic advances in musculoskeletal disease 2022; (14()):1759720X221093211 doi:10.1177/1759720X221093211.
PMID: 35510170
18
A case report: Guillain-Barré syndrome probably associated with TNF inhibitor in Blau syndrome.
Han X, Jin Y, Liu C, et al.
BMC pediatrics 2026; (26(1)):87 doi:10.1186/s12887-025-05987-w.
PMID: 41491690
19
Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.
Sarens IL, Casteels I, Anton J, et al.
American journal of ophthalmology 2018; (187()):158-166 doi:10.1016/j.ajo.2017.08.017.
PMID: 28887115
20
Long-Term Visual Outcome of Patients with Blau Syndrome.
Kreps EO, Al Julandani D, Guly CM, et al.
Ocular immunology and inflammation 2024; (32(8)):1728-1732 doi:10.1080/09273948.2023.2293922.
PMID: 38180755
21
Uveitis despite adalimumab therapy in Blau syndrome.
Takasaki T, Watanabe M, Kawahara Y, Kaburaki T
BMJ case reports 2026; (19(10)) doi:10.1136/bcr-2026-275641.
PMID: 42833844

This page is for informational purposes only and does not constitute medical advice about your child's Blau syndrome treatment. Do not start, stop, taper, or change immunosuppressive medicines or steroid eye drops without guidance from the treating team.